Evolus, Inc. - Common Stock (NQ:EOLS)

7.660 +0.290 (+3.93%)

Delayed Quote Updated: 12:24 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 06, 2025

Via Benzinga

Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket ↗

August 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 05, 2025

Via Benzinga

Top movers in Tuesday's after hours session ↗

August 05, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

A Look Ahead: Evolus's Earnings Forecast ↗

August 04, 2025

Via Benzinga

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 05, 2025

From Evolus

Via Business Wire

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

July 31, 2025

From Evolus

Via Business Wire

Evolus to Report Second Quarter Financial Results on August 5, 2025

July 22, 2025

From Evolus

Via Business Wire

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Assessing Evolus: Insights From 6 Financial Analysts ↗

March 05, 2025

Via Benzinga

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11, 2025

From Evolus

Via Business Wire

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

July 09, 2025

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 13, 2025

From Evolus

Via Business Wire

Evolysse™ Recognized in 2025 Shape Skin Awards

June 10, 2025

From Evolus

Via Business Wire

Evolus Announces Departure of its Chief Financial Officer

May 27, 2025

From Evolus

Via Business Wire

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 22, 2025

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025

From Evolus

Via Business Wire

What Analysts Are Saying About Evolus Stock ↗

May 08, 2025

Via Benzinga

Evolus Reports First Quarter 2025 Results

May 07, 2025

From Evolus

Via Business Wire

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

May 05, 2025

From Evolus

Via Business Wire

Evolus to Report First Quarter Financial Results on May 7, 2025

April 23, 2025

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 18, 2025

From Evolus

Via Business Wire

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 17, 2025

Via Benzinga

Evolus Announces Commercial Launch of Evolysse™

April 16, 2025

From Evolus

Via Business Wire

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

April 15, 2025

From Evolus

Via Business Wire

Breaking Down Evolus: 8 Analysts Share Their Views ↗

April 09, 2025

Via Benzinga

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

March 25, 2025

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 21, 2025

From Evolus

Via Business Wire

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas ↗

March 10, 2025

There's a lot going on for investors.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.